Researchers identified a distinctive profile of cytokine activity in women with endometriosis, which could lead to the development of a clinically useful patient stratification system.
Researchers identified a distinctive profile of cytokine activity in women with endometriosis that could be a signature for developing a patient stratification system similar to what is used for breast cancer patients.
The findings are described in a recent issue of Science Translational Medicine and are offered as an early step in trying to better understand the disease.
- Researchers have identified a distinctive profile of cytokine activity in women with endometriosis that could serve as a signature for the disease.
- The aim would be to develop a patient stratification system similar to what is used for breast cancer patients.
- More research is needed.
"This paper isn't to say we discovered the answer. We're trying to start a conversation with a broad translational science community about this because it is such a terrible disease," said Linda G. Griffith, PhD, of the Center for Gynepathology Research at MIT and one of the authors of the paper. "We found something really interesting, but it's only the tip of the iceberg, and if other clinicians are interesting [sic] in setting up a similar study with their patients, we're happy to talk about collaborating with them."
By analyzing peritoneal fluid from 77 patients who reported a wide range of symptom severity from endometriosis, the researchers were able to see the profile of cytokine activity associated with ovarian and rectovaginal lesions. The pattern, which included 13 cytokines, also negatively correlated with fertility, the study reported.
Many of the molecules in the discovered signature are secreted by macrophages, a type of immune cell that acts as a sentinel, the researchers reported.
The analysis suggests there is a clinically relevant inflammatory network that may serve as an objective measure for guiding treatment decisions for endometriosis, as well as potentially providing an endpoint for assessing efficacy of new treatments aimed at the inflammatory mechanisms driving the disease progression, the authors said.
Next, the scientists plan to study tissue from subsets of the patients to further examine those with infertility and women with deeply infiltrating lesions into the colon and other pelvic organs, according to a news release about the study.
Phase 2b safety data for Sildenafil Cream against FSAD reported
August 26th 2024In a recent study published in The Journal of Sexual Medicine, Sildenafil Cream, 3.6% was indicated as safe and well-tolerated for use against female sexual arousal disorder in healthy premenopausal women.
Read More
Study: Pelvic floor dilator reduces pelvic floor muscle injury during vaginal delivery
August 6th 2024A new pilot study published in the International Urogynecology Journal found that Materna Medical’s Prep Device, a pelvic floor dilator, reduced full levator ani muscle avulsion during vaginal delivery in first-time mothers.
Read More
Similar success rates for synthetic and nonsynthetic slings in SUI treatment
July 31st 2024A study found that both synthetic and nonsynthetic slings show similar success rates for treating stress urinary incontinence in women, with synthetic slings demonstrating improved operative outcomes and reduced complications.
Read More
First hysterectomy using miniaturized MIRA Surgical System performed
July 30th 2024Virtual Incision Corporation has announced the successful performance of the first benign hysterectomy using their miniaturized robotic-assisted surgery device, MIRA, in a clinical trial assessing its safety and efficacy.
Read More